Lyell Immunopharma, Inc. (LYEL)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 8 | 7 | 34 | 13 |
| Research and development | 34,857 | 43,447 | 39,500 | 40,261 |
| Other operating loss (income), net | -1,062 | 119 | 730 | 976 |
| Impairment of long-lived assets | 1,443 | - | - | - |
| General and administrative | 9,786 | 14,046 | 11,769 | 12,256 |
| Total operating expenses | 47,148 | 57,374 | 50,539 | 51,541 |
| Loss from operations | -47,140 | -57,367 | -50,505 | -51,528 |
| Other income (expense), net | 1,180 | 1,310 | -43 | -645 |
| Interest income, net | 3,276 | 3,862 | 5,965 | 6,364 |
| Impairment of other investments | - | - | - | - |
| Total other income, net | 4,456 | 5,172 | 5,922 | 5,719 |
| Net loss | -42,684 | -52,195 | -44,583 | -45,809 |
| Net unrealized (loss) gain on marketable securities | -101 | -133 | 1,157 | 7 |
| Comprehensive loss | -42,785 | -52,328 | -43,426 | -45,802 |
| Net loss per common share, basic (in dollars per share) | -2.89 | -0.18 | -0.17 | -0.18 |
| Net loss per common share, diluted (in dollars per share) | -2.89 | -0.18 | -0.17 | -0.18 |
| Weighted-average shares used to compute net loss per common share, basic (in shares) | 14,793,000 | 295,098,000 | 256,309,000 | 255,398,000 |
| Weighted-average shares used to compute net loss per common share, diluted (in shares) | 14,793,000 | 295,098,000 | 256,309,000 | 255,398,000 |